« Return to News | Awards & Advancement

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

In this position, Reed will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the company's regulatory initiatives. Reed brings over 25 years of experience, in medical practice and in the biotechnology/pharmaceutical sector, including six years with Clinical Data, a biopharmaceutical company that was acquired by Forest Laboratories.

Most recently, Reed served as chief medical officer at Clinical Data from 2005 through 2011, after the company merged with Genaissance Pharmaceuticals, where she had served as vice president of medical affairs since 2003. During her tenure at Clinical Data, Reed was responsible for the design and management of two successful consecutive phase III clinical trials for Viibryd, which is used in the treatment of major depressive disorder in adults. Prior to her time at Genaissance, Reed served as associate medical director in pulmonary medical research at Bayer Pharmaceuticals.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.